High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis

Qu Chen1, Bin Xu2,3, Lei Lan1, Da Yang4, Min Yang4, Jingting Jiang2,3, Binfeng Lu4 & Yueping Shen1

Interleukin-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6/IL-6R signaling pathway, in particular, has been proposed to be a pivotal cytokine promoting ovarian cancer progression. This study aimed to elucidate potential clinical and biological function of IL-6R mRNA expression in ovarian cancer. We used the keywords “ovarian cancer” and searched through GEO database and finally a total of 7 studies together with TCGA database were incorporated in this analysis. We used CutoffFinder to determine a cutoff point and stratified patients into two groups and found that high-expression of IL-6R mRNA in tumor tissues was a positive prognostic factor for overall survival. Simultaneously, high expression level of IL-6R mRNA correlates with better survival of patients who had additional chemotherapy treatment. These analyses suggested a possible role of tumoral expression of IL-6R in ovarian cancer. In conclusion, our results showed that mRNA levels of IL-6R in ovarian cancer was positively associated with better prognosis and sensitivity to chemotherapy and can potentially be used as a prognostic marker for this cancer.

Ovarian cancer is the leading lethal gynecological cancer worldwide. It accounts for approximately 200,000 new cases per year globally1. The poor prognosis is partly due to ovarian cancer usually does not show symptoms until it has been widespread2. In the past 20 years, the therapeutic effect of malignant epithelial ovarian tumor has not been improved, 5 year survival rate remained around 30–40%, and the mortality ranks first in gynecologic malignancies. Malignant epithelial ovarian tumor has become a serious threat to women's life and health. The composition of ovarian tissue is very complex, which has the most organ types of primary tumors.

Tumor microenvironment (TME) is a pathological environment composed of tumor cells, stromal cells, cytokines and immune cells1. It has the characteristics of hypoxia, acidosis and interstitial hypertension3. Ovarian cancer is immunogenic tumor, using many immunosuppressive methods to evade immune elimination, and mainly spread through peritoneal implants and direct spread. Understanding cytokines, immune and inflammatory responses in the TME may be the key to understand the progression of ovarian cancer.

Recent data suggested that a broad spectrum of inflammatory factors are involved in the development and progression of ovarian cancer5. Hence, identifying new additional prognostic and predictive biomarkers may help identify high risk patients, predict outcome of ovarian cancer and even offer a therapeutic strategy. There are more than 16 different cytokines together with corresponding receptors expressed in normal ovaries6. And several particular cytokines and/or their receptors were expressed abnormally7. Interleukin-6 (IL-6), in particular, has been proposed to be a pivotal cytokine promoting ovarian cancer progression. IL-6 signaling through Interleukin-6 receptor (IL-6R)

1Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Department of Epidemiology and Biostatistics, School of Public Health, Soochow University, Suzhou, Jiangsu Province, China. 2Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. 3Jiangsu Engineering Research Center for Tumor Immunotherapy, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. 4Department of Immunology, University of Pittsburgh School of Medicine, E1040, Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, USA. 5Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, USA. Qu Chen and Bin Xu contributed equally to this work. Correspondence and requests for materials should be addressed to Y.S. (email: shenyueping@suda.edu.cn)
can lead to cell survival, proliferation, angiogenesis, and confers resistance to apoptosis induced by conventional therapies through several pathways. Antagonizing IL-6/IL-6R signaling was accepted to have therapeutic activity through inhibition of cytokine network in ovarian cancer cell. Increased expression of IL-6R protein has been observed in ovarian cancer cell lines, cancer tissue, malignant ascites and serum. Kim et al. demonstrated that IL-6 binding to IL-6R increases invasion in ascites. Isobe et al. demonstrated that high IL-6R protein expression in cancer tissue showed significantly worse progression free survival (PFS) than those who had low or negative expression. Therefore, blockade of anti-IL-6/IL-6R signaling has been proposed as a therapeutic approach for ovarian cancer. Indeed, Tocilizumab, an anti-IL-6R monoclonal antibody, in combination with chemotherapy, has shown an acceptable safety profile and a possible immunological benefit in patients with advanced ovarian cancer in a phase I trial. However, clinical benefit for this approach has not been demonstrated. Despite evidences supported a possible protumor role of IL-6R in ovarian cancer, other studies suggested otherwise. Coward et al. have found no association between IL-6R protein expression and survival of patients with ovarian cancer. It has also been found that tumors with a high expression of IL-6R displayed a longer disease-specific survival (DSS), especially in late stage tumors. Thus, the exact role of IL-6R during ovarian development has therefore not been resolved.

In the present study, we firstly analyzed the correlation between the IL-6R mRNA level and its prognostic value in ovarian cancer. We also tried to understand the potential effect of IL-6R on TME and the clinical significance in target-therapy.

**Results**

**Study characteristics.** A total of 7 related publications were identified from the NCBI Pubmed and Gene Expression Omnibus (GEO) database in NCBI (GSE9891, GSE17260, GSE26193, GSE26712, GSE32062, GSE49997, GSE63885). Including TCGA, there were 8 datasets that were analyzed in this article. In the initial screening, a total of 463 potentially relevant datasets were selected for keyword retrieval. 45 datasets were retrieved after screening sample size and organism. After reading summary and the clinic outcome of those data, a total of 7 microarray data that met the inclusion criteria were included in the present study (Fig. 1). Table 1 showed the baseline characteristics of all included studies. Data of 1735 patients from Australia, Japan, France,
America, Vienna, Poland and Singapore were included in this analysis. All of those data reported overall survival (OS), mRNA expression level of IL-6R.

The eight eligible datasets included in this meta-analysis have been performed a quality assessment according to Newcastle-Ottawa Quality Assessment Scale (NOS). The quality score span was from 6 to 9 and the mean score is 7.5. Thus, all of those eight studies were included in following analysis.

**Overall survival.** Eight studies provided suitable data for OS analysis. Univariate analysis and multivariate analysis were respectively carried out for each article (Supplementary Table S1). P values, HRs and 95% CIs of IL-6R mRNA in each article were shown in Supplementary Table S2 and Fig. 2. As there was no obvious statistical heterogeneity in all of those 8 datasets both in univariate survival analysis and multivariate survival analysis ($I^2 = 0.0\%$, $P = 0.999$; $I^2 = 0.0\%$, $P = 0.999$), a fixed-effects model was used to calculate the pooled HR. Overall, this meta-analysis demonstrated that a higher expression of IL-6R mRNA was significantly associated with better OS (pooled HR = 0.62; 95% CI = 0.45–0.86; $P = 0.004$ in univariate analysis; pooled HR = 0.63; 95% CI = 0.45–0.86; $P = 0.005$ in multivariate analysis). The forest plots of study-specific HRs for OS were presented in Fig. 3.

We performed sensitivity analysis using the fixed-effects model by sequential excluding individual study, and it did not substantially change the results, indicating that the results were credible (Fig. 4).

Funnel plots, Egger's and Begg's tests were used to evaluate the publication bias of all 8 studies. Visual inspection of Begg's funnel plot (Supplementary Fig. S1) indicated no evidence of significant publication bias. Begg's test, $P = 0.083$; Egger's test, $P = 0.315$.

**Stratification analysis of IL6R mRNA on survival.** We hypothesized that the use of medications affects the effect of IL-6R. In this article, there are two datasets (GSE9891, TCGA) that embody clinical treatment information and the survival analysis results were listed in Supplementary Table S3 and Fig. 5. Interestingly, in patients who had additional chemotherapy treatment, high expression level of IL-6R mRNA seemed to have better survival (HR = 0.495; 95% CI = 0.317–0.772; $P = 0.002$ for platinum treatment in GSE9891; HR = 0.438; 95% CI = 0.254–0.755; $P = 0.003$ for taxane treatment in GSE9891; HR = 0.697; 95% CI = 0.533–0.911; $P = 0.008$ for postoperative chemotherapy treatment in TCGA). While in patients who had no chemotherapy treatment, IL-6R expression is not associated with prognosis. ($P$ values were 0.210, 0.897 and 0.538, respectively.)

**Correlation between IL-6 and IL-6ST.** The IL-6 receptor is a protein complex consisting of an alpha chain, IL-6R, and IL-6 signal transducer (IL-6ST). Relationship between the mRNA expression of IL-6 and IL-6R, the relationship between IL-6 and IL-6ST, and between IL-6R and IL-6ST were all analyzed in those eight datasets. Interestingly, there was no statistically significant association between IL-6 and IL-6R or between IL-6R and IL-6ST. However, in five datasets, IL-6 was significantly associated with IL-6ST. And more importantly, analysis of 6 studies showed a higher correlation between IL-6 and IL-6ST in those patients who had a higher expression level of IL-6R mRNA. Then we performed a meta-analysis exploring the correlation between IL-6 and IL-6ST depending on the expression level of IL-6R based on Fisher's z transformation of correlations. The pooled correlation coefficient were 0.225 for all patients, 0.310 for patients who had higher IL-6R expression and 0.182 for patients who had lower IL-6R expression (shown in Table 2).

**Biological processes and pathway analysis.** Functional enrichment analysis on IL-6R and the most related genes was performed (all those genes were shown in Supplementary Table S4). Supplementary Table S5 lists the top 10 biological processes and pathway for its enrichment. One of the most significant biological processes is inflammatory response (GO: 0006954, $P = 1.18E-06$). Results also showed that those genes enriched in immune response (GO: 0045087, innate immune response: GO: 0002684, antigen processing and presentation, $P = 1.44E-04$), phagosome (GO: 0044281, $P = 2.05E-03$), cytokine-cytokine receptor interaction (GO: 0040050, $P = 0.92E-04$) and chemokine-chemokine receptor interaction (GO: 0040051, $P = 0.63E-04$) were all belong to immune response.

The most important pathway is antigen processing and presentation (hsa04062, $P = 3.04E-09$). As with the results of biological processes, pathway analysis also shows that these genes are involved in immune responses, eg. antigen processing and presentation (hsa04062, $P = 3.04E-09$), phagosome (hsa04145, $P = 1.16E-04$), graft-versus-host disease (hsa05332, $P = 9.20E-05$), allograft rejection (hsa05330, $P = 4.53E-04$). Signaling pathway of bacteria and viruses infections are also included.

**Discussion**

Ovarian cancer is the most common and serious threat to women’s life and health. Cytokines and chemokines play an important role in the development and progression of ovarian cancer through various mechanisms. To study the TME of ovarian cancer and to explore the meaning on the biological behavior of ovarian cancer are of great importance for the clinical treatment of ovarian cancer.

IL-6/IL-6R signaling was proved to play a significant role in the progression of ovarian cancer. IL-6R mRNA encodes a subunit of the IL-6 receptor complex. IL-6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. It also has additional roles in a variety of other processes such as metabolism and embryonic development. Dysfunction of the complex regulatory cytokine network might lead to acute and chronic inflammation, autoimmune diseases or neoplastic disorders. IL-6 acts as a part of the receptor for interleukin 6. Enrichment analysis of IL-6R and its most relevant genes did show that the most significant biological processes were inflammatory response and immune response. Pathway analysis also showed that these genes were most involved in immune responses.

Although Rath et al. have reported that expression of IL-6R mRNA was found to be up-regulated in ovarian malignancies, no study has indicated the prognostic impact of IL-6R mRNA expression in ovarian cancer tissues. To our knowledge, this is the first report that reused the published raw data and showed that high level of IL-6R mRNA expression was an independent factor for ovarian cancer patients. And this was consistent
with Wouters M’s finding that a high expression of IL-6R protein in ovarian cancer tissue was related to a better DSS. Simultaneously, GSE9891 and TCGA datasets contain important treatment information, therefore, we analyzed the clinical significance of IL-6R mRNA with or without relevant treatment. Interestingly, high level of IL-6R mRNA expression was also a protective factor for patients with platinum or taxane or postoperative...
chemotherapy treatment, which could indicate that high expression of IL-6R mRNA might improve the sensitivity of chemotherapeutic agents. Although there were no statistical significance of IL-6R mRNA expression level in patients without those treatments in our study, considering the small sample size (16, 60 and 29, respectively), whether there was an association between them should be confirmed by other data.

IL-6R is a part of the receptor for interleukin 6 which binds to IL-6 with low affinity, but does not transduce a signal. IL-6ST is necessary for this signal activation. Analysis of those eight selected datasets revealed that there was no significant correlation between IL-6R and IL-6 or between IL-6R and IL-6ST. However, IL-6 was significantly associated with IL-6ST in five datasets. The pooled correlation coefficients for IL-6 and IL-6ST were 0.310 and 0.182 in patients with IL6R expression in top 25% and patients with IL6R expression in bottom 25%, indicating that the higher the expression of IL-6R, the higher the correlation between IL-6 and IL-6ST. So we deduce that the expression level of IL-6R may affect the binding of IL-6 and IL-6ST and may further affect the activation of downstream pathways, such as Jak-STAT signaling pathway, PI3K-Akt signaling pathway, TNF signaling pathway and etc.

**Figure 3.** Forest plots of studies evaluating hazard ratios of high IL-6R mRNA expression in ovarian cancers for OS. (a) univariate analysis. (b) multivariate analysis.

---

| Study          | %       | HR (95% CI) | Weight |
|----------------|---------|-------------|--------|
| Tothill R. (2008) | 0.54 (0.21, 1.37) | 12.50   |
| Yoshihara K. (2010) | 0.55 (0.18, 1.67) | 8.54   |
| Mateescu B. (2011) | 0.60 (0.22, 1.62) | 10.98  |
| Birrer MJ. (2015)  | 0.67 (0.29, 1.55) | 15.13  |
| Gonzales KA. (2015) | 0.59 (0.23, 1.50) | 12.37  |
| Pils D. (2014)     | 0.50 (0.15, 1.68) | 7.31   |
| Lisowska K. (2014) | 0.68 (0.26, 1.82) | 11.22  |
| TCGA (2015)        | 0.72 (0.36, 1.44) | 21.96  |
| Overall (I–squared = 0.0%, p = 0.999) | 0.62 (0.45, 0.86) | 100.00 |

---

| Study          | %       | HR (95% CI) | Weight |
|----------------|---------|-------------|--------|
| Tothill R. (2008) | 0.53 (0.21, 1.34) | 12.52   |
| Yoshihara K. (2010) | 0.55 (0.18, 1.69) | 8.60   |
| Mateescu B. (2011) | 0.61 (0.23, 1.65) | 11.06  |
| Birrer MJ. (2015)  | 0.69 (0.30, 1.61) | 15.22  |
| Gonzales KA. (2015) | 0.60 (0.23, 1.51) | 12.48  |
| Pils D. (2014)     | 0.49 (0.14, 1.71) | 6.94   |
| Lisowska K. (2014) | 0.63 (0.24, 1.70) | 11.20  |
| TCGA (2015)        | 0.76 (0.37, 1.53) | 21.96  |
| Overall (I–squared = 0.0%, p = 0.999) | 0.63 (0.45, 0.87) | 100.00 |
However, some details need to be further refined. First, this study included only eight eligible datasets, which resulted in relatively insufficiency data in the subgroup analyses. Second, due to the lack of some pivotal clinical parameters, association between those parameters and IL-6R mRNA expression can’t be shown, such as metastasis, treatment and so on. Although we found that high level of IL-6R mRNA expression was a protective factor for patients with chemotherapy treatment, this result should be verified by other clinical randomized trials. Third, there are six publications that reported stage of all patients, but the number of patients varies greatly in each stage. Thus, we reported both univariate and multivariate analysis results in this paper.

In conclusion, our results showed that mRNA levels of IL-6R in ovarian cancer was associated with better prognosis and sensitivity to chemotherapy and can potentially be used as a prognostic marker for this cancer. Taking the limitation of our study into consideration, the results should be regarded cautiously. Further prospective studies available of pivotal parameters are needed to verify the prognosis value of IL-6R in ovarian cancer patients. And the process of translation from mRNA to protein, microRNA regulation and post-translational modification need further study.

Materials and Methods

Search strategy. Electronic databases were searched through GEO database (last update by January 10, 2017) using the keywords “ovarian cancer” (http://www.ncbi.nih.gov/geo). Database searching was carried out by two researchers independently (Min Yang and Lei Lan).

Data extraction and quality assessment. Data from all 8 eligible datasets was abstracted independently by two authors, using information recorded as follows: first author's surname, publication year, origin of population, sample number, tumor stage, follow-up period and clinic outcome. Seven microarray datasets together with TCGA which embody IL-6R mRNA expression and survival data are collected, HRs and 95% CIs were evaluated by Cox proportional hazards model.

The quality of eight eligible studies was assessed according to the Newcastle-Ottawa Quality Assessment Scale (NOS) by two researchers independently. The quality scores span from 0 to 9, and higher the score is, higher the quality is.

Statistical analysis. For those public microarray data, gene expression was represented by metric variables. We use Cutoff Finder (http://molpath.charite.de/cutoff) to determine a cutoff point and stratify patients into two groups. The range of IL-6R mRNA values for each data and the corresponding cutoff value were listed in Supplementary Table S6. HRs and 95% CIs were calculated to measure the effective prognostic value of expression of IL-6R mRNA in ovarian cancer patients. Heterogeneity of HR was appraised by using the Cochran Q and I² test. A random-effect model (the DerSimonian-Laird method) was applied when \( P < 0.1 \) or \( I^2 > 50\% \). When heterogeneity was absent, a fixed-effect model (the Mantel-Haenszel method) was employed.

Publication bias was assessed by Begg's rank correlation method and Egger's weighted regression method. All \( P \) values were two tailed, and all analyses were carried out using STATA software package (version 12.0) (Stata Corp LP, College Station, TX, USA).

For each dataset, we calculated the correlation coefficient between IL-6R and the remaining genes, and then matched the coefficients in all the eight datasets. Genes with absolute correlation coefficient which were greater than 0.3 in three or more publications were extracted. 116 genes were included in subsequent analysis (Supplementary Table S4).

Functional enrichment analysis of IL-6R and its related genes allows the identification of biological processes or functions. In this study, Gene Ontology Consortium (http://www.geneontology.org/) was used to analyze gene enrichment and to explore the biological processes of gene enrichment. Pathway mapping of IL-6R was done on the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/summary.jsp).
Figure 5. Stratification analysis of IL-6R mRNA on survival. (a) Kaplan-Meier analysis of patients with platinum treatment in dataset GSE9891. (b) Kaplan-Meier analysis of patients with no platinum treatment in dataset GSE9891. (c) Kaplan-Meier analysis of patients with taxane treatment in dataset GSE9891. (d) Kaplan-Meier analysis of patients with no taxane treatment in dataset GSE9891. (e) Kaplan-Meier analysis of patients with additional radiation therapy dataset in TCGA. (f) Kaplan-Meier analysis of patients with no additional radiation therapy dataset in TCGA.

Table 2. The Correlation Coefficient between IL-6 and IL-6ST Depend on the Expression Level of IL-6R.
References

1. Narod, S. Can advanced-stage ovarian cancer be cured? Nature reviews. Clinical oncology 13, 255–261, doi:10.1038/ nronc.2015.224 (2016).

2. Ozols, R. F. Challenges for chemotherapy in ovarian cancer. Annals of oncology: official journal of the European Society for Medical Oncology 17(Suppl 5), v181–187, doi:10.1093/annonc/mdy978 (2006).

3. Hede, K. Environmental protection: studies highlight importance of tumor microenvironment. Journal of the National Cancer Institute 96, 1120–1121, doi:10.1093/jnci/96.15.1120 (2004).

4. Fidler, I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature reviews. Cancer 3, 453–458, doi:10.1038/nrc1098 (2003).

5. Maccio, A. & Maseddu, C. Inflammation and ovarian cancer. Cytokine 58, 133–147, doi:10.1016/j.cyto.2012.01.015 (2012).

6. Burke, F., Relf, M., Negus, R. & Balkwill, F. A cytokine profile of normal and malignant ovary. Cytokine 8, 578–585, doi:10.1006/cytb.1996.0077 (1996).

7. Nash, M. A., Ferrandina, G., Gordinier, M., Loercher, A. & Freedman, R. S. The role of cytokines in both the normal and malignant ovary. Endocrine-related cancer 6, 93–107 (1999).

8. Dijkstra, E. M., Welters, M. J., Nortier, J. W., van der Burg, S. H. & Kroep, I. R. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Current pharmaceutical design 18, 3816–3827 (2012).

9. Guo, Y. et al. Effects of siltuximab on the IL-6–induced signaling pathway in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 5759–5769, doi:10.1158/0008-4321-cto-1095 (2010).

10. Isobe, A. et al. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PloS one 10, e0118080, doi:10.1371/journal.pone.0118080 (2015).

11. Rath, K. S., Funk, H. M., Bowling, M. C., Richards, W. E. & Drew, A. F. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. American journal of obstetrics and gynecology 203(230), e231–238, doi:10.1016/j.ajog.2010.03.034 (2010).

12. Lo, C. W. et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer research 71, 424–434, doi:10.1158/0008-5472.can-10-1496 (2011).

13. Kovacs, E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomedicine & pharmacotherapy = Biomedicina & farmacoterapia 55, 391–396 (2001).

14. Kim, S. et al. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro. Oncotarget 7, 83148–83159, doi:10.18632/oncotarget.13074 (2016).

15. Colomiere, M. et al. Cross talk of signals between EGF and IL-6R through JAK2/STAT3 mediates epithelial-mesenchymal transition in ovarian carcinomas. British journal of cancer 100, 134–144, doi:10.1038/bjc.6604794 (2009).

16. Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer treatment reviews 38, 904–910, doi:10.1016/j.ctrv.2012.04.007 (2012).

17. Dijkstra, E. M. et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Annals of oncology: official journal of the European Society for Medical Oncology 26, 2141–2149, doi:10.1093/annonc/mdv309 (2015).

18. Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 17, 6083–6096, doi:10.1158/0008-4321-cto-11-0945 (2011).

19. Wouters, M. et al. Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology 3, e262397, doi:10.4161/21624011.2014.962397 (2014).

20. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research 14, 5198–5208, doi:10.1158/0008-4322.ccr-08-0196 (2008).

21. Yoshihara, K. et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PloS one 5, e9615, doi:10.1371/journal.pone.0009615 (2010).

22. Matescu, B. et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nature medicine 17, 1627–1635, doi:10.1038/nm.2521 (2011).

23. Vathipadiekal, V. et al. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical cancer research: an official journal of the American Association for Cancer Research 21, 4960–4969, doi:10.1158/0008-4321-crr-14-3173 (2015).

24. Gonzales, K. A. et al. Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways. Cell 162, 564–579, doi:10.1016/j.cell.2015.07.001 (2015).

25. Pils, D. et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer science 103, 1334–1341, doi:10.1111/csc.12096 (2012).

26. Lisowska, K. M. et al. Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study. Frontiers in oncology 4, 6, doi:10.3389/fonc.2014.00006 (2014).

27. Yao, X. et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmaceutics & therapeutics 141, 125–139, doi:10.1016/j.pharmthera.2013.09.004 (2014).

28. Pulsatelli, L. et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk, Arthritis and rheumatism 59, 1147–1154, doi:10.1002/art.23924 (2008).

29. Montero-Julian, F. A. The soluble IL-6 receptors: serum levels and biological function. Cellular and molecular biology (Noisy-le-Grand, France) 47, 583–597 (2001).

30. Budczies, J. et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PloS one 7, e51862, doi:10.1371/journal.pone.0051862 (2012).

Acknowledgements

This work was supported by funding from National Science and Technology Support Program (2015BAA12B12), National Natural Science Foundation of China (31570877, 31570908), Special Funds of Science and Technology of the People’s Livelihood Construction Condition of Jiangsu Province (BL2014034), Science and Technology Bureau foundation application project of Changzhou (CJ20150918), the Key R&D Project of Science and Technology Department of Jiangsu Province (BE2015633), the Program of Jiangsu Engineering Research Center for Tumor Immunotherapy (BM2014400).

Author Contributions

B.L. and J.J. designed, interpreted and presented results for group discussions. L.L. and M.Y. collected public datasets. Q.C. and B.X. provided methods, description of results, figures, and tables for the manuscript. Q.C. and B.X. wrote and organized the manuscript, with editorial input from Y.S., D.Y., J.J. and B.L.
Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-09333-8

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017